Carisma Therapeutics Inc. (CARM): Nasdaq/NYSE listing notice — Carisma Therapeutics receives Nasdaq bid price deficiency notice; has until July 7, 2025 to regain compliance

Carisma Therapeutics Inc.

Received Nasdaq notice on Jan 6, 2025 for non-compliance with minimum bid price of $1.00 per share.
Company has 180 days, until July 7, 2025, to regain compliance by having closing bid price ≥$1.00 for 10 consecutive business days.
If compliance not achieved, may transfer to Nasdaq Capital Market for additional 180-day period, subject to meeting other listing standards.
Company intends to monitor bid price and consider options including potential reverse stock split if needed.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 6, 2025, Carisma Therapeutics Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upo

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Carisma Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 6, 2025, Carisma Therapeutics Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of its common stock for the last 38 consecutive business days, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”), which requires the Company to maintain a minimum bid price of $1.00 per share. The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or t

View on SEC.gov

Browse all listing & compliance notices →

Carisma Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-002522

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.